EXTH-05. miR-34a INHIBITS GLIOBLASTOMA CELL PROLIFERATION AND SENSITIZES TO TEMOZOLOMIDE

Glioblastoma (GBM) is the most common primary brain tumor with a median survival of 14.5 months, despite maximal therapy consisting of surgical resection, radiation and temozolomide (TMZ). Genetic profiling has shown an average of three driver mutations localized to the p53, Rb and receptor tyrosine...

Full description

Saved in:
Bibliographic Details
Published in:Neuro Oncol
Main Authors: Khan, Muhammad Babar, Ruggieri, Rosamaria, Tran, Nhan, Sarkaria, Jann, Symons, Marc
Format: Artigo
Language:Inglês
Published: Oxford University Press 2017
Subjects:
Abstracts
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC5691989/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/nox168.301
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items